SANES

10.662

-0.43%↓

BBVA

19.435

-0.87%↓

BNP

93.66

+0.01%↑

CABK

11.52

-0.04%↓

INGA

26.005

-1.12%↓

SANES

10.662

-0.43%↓

BBVA

19.435

-0.87%↓

BNP

93.66

+0.01%↑

CABK

11.52

-0.04%↓

INGA

26.005

-1.12%↓

SANES

10.662

-0.43%↓

BBVA

19.435

-0.87%↓

BNP

93.66

+0.01%↑

CABK

11.52

-0.04%↓

INGA

26.005

-1.12%↓

SANES

10.662

-0.43%↓

BBVA

19.435

-0.87%↓

BNP

93.66

+0.01%↑

CABK

11.52

-0.04%↓

INGA

26.005

-1.12%↓

SANES

10.662

-0.43%↓

BBVA

19.435

-0.87%↓

BNP

93.66

+0.01%↑

CABK

11.52

-0.04%↓

INGA

26.005

-1.12%↓

Home・Stock List・Sartorius Stedim Biotech.

Sartorius Stedim Biotech.

Closed

SectorFinance

179.2 -2.08

Buy Sell

Overview

Share price change

24h

Current

Min

178.5

Max

184.8

Key metrics
By Trading Economics
Income	41M 88M
Sales	-11M 762M
P/E Sector Avg	64.546 41.721
EPS	1.17
Profit margin	11.569
Employees	10,456
EBITDA	26M 225M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+26.64% upside

Dividends
By Dow Jones
Next Earnings	23 Jul 2026

Market Stats
By TradingEconomics
Market Cap	-897M 17B
Previous open	181.28
Previous close	179.2

News Sentiment

By Acuity

100%

414 / 439 Finance

Sartorius Stedim Biotech. Chart

Past performance is not a reliable indicator of future results.

Related News

5 Jun 2026, 19:20 UTC

Major Market Movers

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 Jun 2026, 21:27 UTC

Earnings

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 Jun 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5 Jun 2026, 20:20 UTC

Acquisitions, Mergers, Takeovers

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 Jun 2026, 20:19 UTC

Acquisitions, Mergers, Takeovers

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 Jun 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 Jun 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 Jun 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5 Jun 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 Jun 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 Jun 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 Jun 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 Jun 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 Jun 2026, 18:33 UTC

Acquisitions, Mergers, Takeovers

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 Jun 2026, 17:50 UTC

Earnings

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 Jun 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 Jun 2026, 16:48 UTC

Acquisitions, Mergers, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 Jun 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 Jun 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5 Jun 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5 Jun 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 Jun 2026, 15:44 UTC

Acquisitions, Mergers, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 Jun 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 Jun 2026, 15:25 UTC

Earnings

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 Jun 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 Jun 2026, 15:16 UTC

Market Talk

Zcash Tumbles After Exploit Found -- Market Talk

5 Jun 2026, 15:09 UTC

Market Talk

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 Jun 2026, 15:07 UTC

Market Talk

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 Jun 2026, 15:05 UTC

Market Talk

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Peer Comparison

Price change

Sartorius Stedim Biotech. Forecast

Price Target

By TipRanks

26.64% upside

12 Months Forecast

Average 232.63 EUR 26.64%

High 262 EUR

Low 210 EUR

Based on 9 Wall Street analysts offering 12 month price targets forSartorius Stedim Biotech. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Sartorius Stedim Biotech. - Dist in the past 3 months.

Sentiment

By Acuity

414 / 439 Finance

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.